Drugs / FB301
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07453069 | Apr → Oct 2026 expected | — | Freya Biosciences ApS | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07481955 | Mar 2026 → Mar 2027 expected | bacterial vaginosis | Freya Biosciences ApS | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FB301 | “The goal of this study is to evaluate how treatment with FB301 affects the balance of vaginal bacteria in women (aged 18-45) with bacterial vaginosis after pre-treatment with...” NCT07481955 ↗ |
| Modality | Other / unclassified | “FB301, a Live Biotherapeutic Product (LBP) comprising consortia of Lactobacillus strains” NCT07481955 ↗ |
| Route | Other | “intravaginal FB301” NCT07481955 ↗ |